Cl.CN(C)CCCN=C=NCC.ON1C2C=CC=CC=2N=N1.[CH3:23][Si:24]([CH3:46])([CH3:45])[C:25]1[CH:26]=[C:27]2[C:31](=[CH:32][CH:33]=1)[N:30]([CH2:34][C:35]1[CH:40]=[CH:39][CH:38]=[C:37]([F:41])[CH:36]=1)[C:29]([C:42](O)=[O:43])=[CH:28]2.[NH2:47][C:48]1[CH:49]=[N:50][C:51]([N:54]2[CH2:57][CH2:56][CH2:55]2)=[CH:52][CH:53]=1.C([O-])(O)=O.[Na+]>CN(C=O)C.CCOC(C)=O>[N:54]1([C:51]2[N:50]=[CH:49][C:48]([NH:47][C:42]([C:29]3[N:30]([CH2:34][C:35]4[CH:40]=[CH:39][CH:38]=[C:37]([F:41])[CH:36]=4)[C:31]4[C:27]([CH:28]=3)=[CH:26][C:25]([Si:24]([CH3:46])([CH3:23])[CH3:45])=[CH:33][CH:32]=4)=[O:43])=[CH:53][CH:52]=2)[CH2:57][CH2:56][CH2:55]198 mg (0.51 mmol) of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and 69 mg (0.51 mmol) of 1-hydroxybenzotriazole (HOBt) are added to a solution, stirred at 20° C. under an inert atmosphere, of 0.16 g (0.47 mmol) of 5-trimethylsilyl-1-[(3-fluorophenyl)methyl]-1H-indole-2-carboxylic acid, prepared according to the protocol described in stage 3.6, in 10 ml of DMF. The reaction mixture is stirred at ambient temperature for 15 minutes. 84 mg (0.56 mmol) of 3-amino-6-(azetidin-1-yl)pyridine, prepared according to the protocol described in stage 1.6, are subsequently added to the reaction mixture. After stirring at 20° C. for 16 h, the reaction mixture is poured into a mixture of 30 ml of a saturated aqueous solution of NaHCO3 and 30 ml of EtOAc. The aqueous phase is extracted with 20 ml of EtOAc. The combined organic phases are washed with 3×30 ml of water, dried over Na2SO4, and then concentrated under reduced pressure. The solid obtained after evaporation of the solvent under reduced pressure is washed with isopropyl ether at reflux, filtered under hot conditions and then dried under reduced pressure. 75 mg of the expected product are thus isolated.